AstraZeneca Results Presentation Deck
Total Revenue ($m)
Q3 dynamics
3,000
2,500
2,000
BioPharmaceuticals
- 9M and Q3 2023
CVRM Total Revenue +19% in 9M 2023 and strong launch brand momentum in R&I
1,500
1,000
500
0
Q3
CVRM
9M 2023 $7.9bn, +19%
Q4
2021
Q1 Q2 Q3
2022
Q4 Q1 Q2
2023
Farxiga Brilinta Lokelma Others
Q3
Farxiga +41%, demand growth outpacing SGLT2i
Lokelma, roxadustat both up >30%
Total Revenue ($m)
1,800
1,600
1,400
Q3 dynamics
1,200
1,000
800
600
400
200
0
CEO Opening Remarks
●
Q3 Q4
2021
Financial Results
R&I
9M 2023 $4.7bn, +9%
Q1
Q2 Q3
2022
Q4
Q1
Fasenra Breztri Tezspire Saphnelo Symbicort Others
Q2
2023
Oncology
Q3
Fasenra, +10%, continued uptake of biologics
Breztri, +69%, to $171m, global share gains
Tezspire, +19% QOQ, strong launches continue
Total Revenue ($m)
BioPharmaceuticals
Q3 dynamics
2,500
2,000
1,500
1,000
500
Rare Disease
Q3 Q4
2021
V&I
9M 2023 $944m
CEO Closing Remarks
Q1 Q2 Q3 Q4 Q1
2022
Q2 Q3
2023
COVID-19 mAbs¹ Beyfortus FluMist Synagis Vaxzevria
COVID-19 medicines $nil in Q3
FluMist +23%, new orders and phasing
Beyfortus, first commercial sales and milestone
All growth rates at CER.
1. COVID-19 mAbs = Evusheld and AZD3152, the antibody currently in development
22 CER = constant exchange rates; CVRM = Cardiovascular, Renal and Metabolism; SGLT2i = sodium-glucose cotransporter 2 inhibitors; R&I= Respiratory and Immunology; QoQ = quarter on quarter; V&I= Vaccine and Immune Therapies; mAbs = monoclonal antibodies.
Collaboration partners: Amgen (Tezspire); Sanofi (Beyfortus).View entire presentation